56 related articles for article (PubMed ID: 12710195)
21. CDK inhibitors in cancer therapy: what is next?
Malumbres M; Pevarello P; Barbacid M; Bischoff JR
Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
[TBL] [Abstract][Full Text] [Related]
22. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects.
Rocha A; Azevedo I; Soares R
J Cell Biochem; 2008 Feb; 103(2):607-14. PubMed ID: 17614352
[TBL] [Abstract][Full Text] [Related]
23. Modulation of vascular smooth muscle cell growth by magnesium-role of mitogen-activated protein kinases.
Touyz RM; Yao G
J Cell Physiol; 2003 Dec; 197(3):326-35. PubMed ID: 14566962
[TBL] [Abstract][Full Text] [Related]
24. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
Krystof V; Cankar P; Frysová I; Slouka J; Kontopidis G; Dzubák P; Hajdúch M; Srovnal J; de Azevedo WF; Orság M; Paprskárová M; Rolcík J; Látr A; Fischer PM; Strnad M
J Med Chem; 2006 Nov; 49(22):6500-9. PubMed ID: 17064068
[TBL] [Abstract][Full Text] [Related]
25. In vitro evaluation of a novel 2,6,9-trisubstituted purine acting as a cyclin-dependent kinase inhibitor.
Giocanti N; Sadri R; Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Favaudon V
Ann N Y Acad Sci; 1999; 886():180-2. PubMed ID: 10667214
[No Abstract] [Full Text] [Related]
26. Detecting hyaluronidase and hyaluronidase inhibitors. Hyaluronan-substrate gel and -inverse substrate gel techniques.
Mio K; Csóka AB; Nawy SS; Stern R
Methods Mol Biol; 2001; 171():391-7. PubMed ID: 11450253
[No Abstract] [Full Text] [Related]
27. Transcriptional kinases: Less is more (or less).
Boyer TG
Nat Chem Biol; 2016 Jan; 12(1):4-5. PubMed ID: 26678610
[No Abstract] [Full Text] [Related]
28. Cyclin-Dependent Kinase Inhibitor-Associated Thromboembolism.
Olson SR; DeLoughery TG; Shatzel JJ
JAMA Oncol; 2019 Feb; 5(2):141-142. PubMed ID: 30543359
[No Abstract] [Full Text] [Related]
29. Small-molecule inhibitors of cyclin-dependent kinases: molecular tools and potential therapeutics.
Walker DH
Curr Top Microbiol Immunol; 1998; 227():149-65. PubMed ID: 9479830
[No Abstract] [Full Text] [Related]
30. Reduction of background in protein kinase assays by electroblotting.
Enke DA; Solomon MJ
Biotechniques; 1997 Jan; 22(1):74-8. PubMed ID: 8994651
[No Abstract] [Full Text] [Related]
31. American Chemical Society--227th annual meeting. Highlights. 28 March - 1 April 2004, Anaheim, CA, USA.
Garvey R; Veryard C
IDrugs; 2004 May; 7(5):426-7. PubMed ID: 15154099
[No Abstract] [Full Text] [Related]
32. Screening with COMPARE analysis for telomerase inhibitors.
Naasani I; Yamori T; Tsuruo T
Methods Mol Biol; 2002; 191():197-207. PubMed ID: 11951607
[No Abstract] [Full Text] [Related]
33. Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples.
Malik SN; Bedolla RG; Hidalgo M; Brattain MG; Kreisberg JI
Methods Mol Med; 2003; 85():135-40. PubMed ID: 12710204
[No Abstract] [Full Text] [Related]
34. Integrated technology platform protein kinases for drug development in oncology.
Sachsenmaier C; Schächtele C
Biotechniques; 2002 Oct; Suppl():101-6. PubMed ID: 12395934
[TBL] [Abstract][Full Text] [Related]
35. Assays for cyclin-dependent kinase inhibitors.
Senderowicz AM; Lahusen T
Methods Mol Med; 2003; 85():39-48. PubMed ID: 12710195
[No Abstract] [Full Text] [Related]
36. Assays for cyclin-dependent kinase inhibitors.
Senderowicz AM
Methods Mol Biol; 2004; 285():69-78. PubMed ID: 15269400
[No Abstract] [Full Text] [Related]
37. Immunohistochemical assays of farnesyltransferase inhibition in patient samples.
Adjei AA
Methods Mol Med; 2003; 85():141-5. PubMed ID: 12710205
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
